Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 20
- Registration Number
- NCT06254560
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT06245707
- Locations
- 🇨🇳
Beijing Friedship Hospital, Beijing, Beijing, China
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-08-19
- Target Recruit Count
- 324
- Registration Number
- NCT06220032
- Locations
- 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma-RecurrentHigh Grade B-Cell Lymphoma-RecurrentPrimary Mediastinal Large B-Cell Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RecurrentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RefractoryDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RefractoryFollicular Lymphoma-Refractory
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Nathan Denlinger
- Target Recruit Count
- 18
- Registration Number
- NCT06209619
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
- Conditions
- Interventions
- Locations
- 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸Local Institution - 0121, New York, New York, United States
🇫🇷Local Institution - 0036, Montpellier, Languedoc-Roussillon, France
BV-AVD-R Treatment Children Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06201507
- Locations
- 🇨🇳
Duan Yanlong, Beijing, China
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-01
- Target Recruit Count
- 108
- Registration Number
- NCT06190301
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT06188676
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.